Latest Content

Among adult patients who have reported a case of invasive pneumococcal disease, researchers address the association of risk factors and recurrent disease.

Lipfendra (enlicitide) showed placebo-adjusted low-density lipoprotein cholesterol reductions of more than 50% in 2 phase 3 trials.

Emerging data show glucagon-like peptide-1 receptor agonists may raise the risk of certain autoimmune diseases compared with other diabetes drugs.

In this episode, Natalie DiPietro Mager, PharmD, PhD, talks with Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, about how pharmacists can address cannabis use in women during adolescence, reproductive years, and older adulthood.

Investigators test 3 repurposed drugs alongside specialist care, finding small, transient fatigue improvements for long COVID fatigue.

With GLP-1 questions creating confusion for Medicare patients, pharmacists are becoming the trusted frontline resource, and the stakes for getting it right have never been higher.

New research links a national surge in poison control calls involving semaglutide to preventable dosing mistakes rather than intentional misuse.

With the goal of optimizing long-term weight-loss treatment, researchers gather insights regarding the lived experiences of glucagon-like peptide-1 users.

Drug shortages drop in 2025, yet long-lasting sterile injectable gaps, rising discontinuations, and fragile supply chains reshape pharmacy work.

Subcutaneous lecanemab-irmb can now be self-administered or given by a caregiver from the first dose, eliminating the requirement for an initial in-clinic intravenous infusion.

This episode meanders the time of the year where pharmacy professionals experience a lull in business, providing them with the perfect opportunity to invest in growth.

Jay Bregman, founder and CEO of Andel, discusses the current GLP-1 landscape and how a new Medicare initiative is designed to improve access to this increasingly popular medication class.

A new analysis shows that socioeconomic status shrinks type 2 diabetes risk far more for nonHispanic white and Asian Americans than for nonHispanic Black and Hispanic Americans.

Researchers assess how these emerging platforms can support medication use across this patient population.

A newly published review traces chikungunya's re-emergence to a record 2025 outbreak in China, and 2 FDA-approved vaccines shape prevention strategy for pharmacists.

Within the arena of chronic nonmalignant pain, researchers explore barriers, facilitators, and strategies for opioid optimization services in community pharmacies.

Diyaben Patel, PharmD, discusses where artificial intelligence is genuinely transforming pharmacy practice.

Exploring retail pharmacy data, specifically among Walgreens locations, researchers assess the impact of closures in socially vulnerable areas.

Price transparency, direct-to-consumer, and digital fulfillment channels are reshaping how patients obtain medications.

Often operating in the shadows, LTC pharmacy is the backbone of medication management for aging and immunocompromised patients.

New case-control study finds that patients with type 2 diabetes and more severe depressive symptoms show higher cortisol, higher hemoglobin A1C, and lower insulin.

A new surveillance study shows pneumococcal vaccine shifts cut key antibiotic resistance for invasive pneumococcal disease.

Among US adults with and without chronic medical conditions, researchers examine social media use for health-related information.

West Nile virus cases rise early in 2026, with Arizona leading with 32 cases.

Prior to the study, researchers report a significant lack of exploration regarding artificial intelligence's use in antimicrobial stewardship programs conducted in pharmacy practice.

In-home pharmacist visits uncover medication risks, improve adherence and deprescribing, and help older adults stay safer at home.

In part 2 of our interview, Esmé Grewal, JD, discusses the key opportunities LTC pharmacies possess in assisting the aging population in medication management.

Atacicept-vymj is the first medication for immunoglobulin A nephropathy that targets both B cell activating factor and a proliferation-inducing ligand inhibitors.

Pharmacists are being asked to serve as the frontline correctors of medical misinformation, but the emotional labor and repetition are compounding the severe burnout crisis.

Through a secret shopper study, researchers assessed the process for obtaining GLP-1 therapy via the internet and the clinical engagement associated with the purchase.

Researchers assess the impact of various pneumococcal conjugate vaccines since the introduction of immunization programming.